These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1323 related items for PubMed ID: 9267717

  • 1. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
    Lo CY, Ho KN, Yuen KY, Lui SL, Li FK, Chan TM, Lo WK, Cheng IK.
    Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
    [Abstract] [Full Text] [Related]

  • 2. Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation.
    Ksouri H, Eljed H, Greco A, Lakhal A, Torjman L, Abdelkefi A, Ben Othmen T, Ladeb S, Slim A, Zouari B, Abdeladhim A, Ben Hassen A.
    Transpl Infect Dis; 2007 Mar; 9(1):16-21. PubMed ID: 17313466
    [Abstract] [Full Text] [Related]

  • 3. Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real-time quantitative DNA PCR assay: correlation with pp67 RNA detection.
    Mengoli C, Cusinato R, Biasolo MA, Cesaro S, Parolin C, Palù G.
    J Med Virol; 2004 Sep; 74(1):78-84. PubMed ID: 15258972
    [Abstract] [Full Text] [Related]

  • 4. Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation.
    Hebart H, Müller C, Löffler J, Jahn G, Einsele H.
    Bone Marrow Transplant; 1996 May; 17(5):861-8. PubMed ID: 8733710
    [Abstract] [Full Text] [Related]

  • 5. Quantitation of cytomegalovirus DNA by real-time polymerase chain reaction in peripheral blood specimens of patients with solid organ transplants: comparison with end-point PCR and pp65 antigen test.
    Allice T, Enrietto M, Pittaluga F, Varetto S, Franchello A, Marchiaro G, Ghisetti V.
    J Med Virol; 2006 Jul; 78(7):915-22. PubMed ID: 16721848
    [Abstract] [Full Text] [Related]

  • 6. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F, Tscheliessnigg KH, Halwachs G, Auer T, Wasler A, Petutschnigg B, Müller H, Freigassner M, Allmayr T, Hipmair G.
    Wien Klin Wochenschr; 1995 Jul; 107(23):718-22. PubMed ID: 8560893
    [Abstract] [Full Text] [Related]

  • 7. Use of PCR serum in diagnosing and monitoring cytomegalovirus reactivation in bone marrow transplant recipients.
    Matsunaga T, Sakamaki S, Ishigaki S, Kohda K, Takeda M, Katoh J, Kuroda H, Hirayama Y, Kusakabe T, Akiyama T, Kuga T, Niitsu Y, Masaoka T, Sagawa T, Matsumoto Y.
    Int J Hematol; 1999 Feb; 69(2):105-11. PubMed ID: 10071460
    [Abstract] [Full Text] [Related]

  • 8. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Pajand O, Ziyaeyan M, Mousavi S, Fatolahzadeh B, Hojabri Z, Bahador A, Abdossamadi Z.
    Exp Clin Transplant; 2008 Jun; 6(2):149-54. PubMed ID: 18816243
    [Abstract] [Full Text] [Related]

  • 9. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
    Solano C, Muñoz I, Gutiérrez A, Farga A, Prósper F, García-Conde J, Navarro D, Gimeno C.
    J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
    [Abstract] [Full Text] [Related]

  • 10. Quantitative PCR in the diagnosis of CMV infection and in the monitoring of viral load during the antiviral treatment in renal transplant patients.
    Piiparinen H, Helanterä I, Lappalainen M, Suni J, Koskinen P, Grönhagen-Riska C, Lautenschlager I.
    J Med Virol; 2005 Jul; 76(3):367-72. PubMed ID: 15902704
    [Abstract] [Full Text] [Related]

  • 11. Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: an intent to find the optimal cut-off value.
    Martín-Dávila P, Fortún J, Gutiérrez C, Martí-Belda P, Candelas A, Honrubia A, Barcena R, Martínez A, Puente A, de Vicente E, Moreno S.
    J Clin Virol; 2005 Jun; 33(2):138-44. PubMed ID: 15911429
    [Abstract] [Full Text] [Related]

  • 12. [Evaluation of cytomegalovirus quantification in blood by the R-gene real-time PCR test].
    Marque-Juillet S, Touzard A, Monnier S, Fernand-Laurent C, Therby A, Rigaudeau S, Harzic M.
    Pathol Biol (Paris); 2010 Apr; 58(2):162-5. PubMed ID: 19854587
    [Abstract] [Full Text] [Related]

  • 13. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
    Yakushiji K, Gondo H, Kamezaki K, Shigematsu K, Hayashi S, Kuroiwa M, Taniguchi S, Ohno Y, Takase K, Numata A, Aoki K, Kato K, Nagafuji K, Shimoda K, Okamura T, Kinukawa N, Kasuga N, Sata M, Harada M.
    Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
    [Abstract] [Full Text] [Related]

  • 14. A prospective study comparing cytomegalovirus antigenemia, DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ transplant recipients.
    Lehto JT, Lemström K, Halme M, Lappalainen M, Lommi J, Sipponen J, Harjula A, Tukiainen P, Koskinen PK.
    Transpl Int; 2005 Dec; 18(12):1318-27. PubMed ID: 16297050
    [Abstract] [Full Text] [Related]

  • 15. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
    Lilleri D, Baldanti F, Gatti M, Rovida F, Dossena L, De Grazia S, Torsellini M, Gerna G.
    J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
    [Abstract] [Full Text] [Related]

  • 16. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients.
    Sanghavi SK, Abu-Elmagd K, Keightley MC, St George K, Lewandowski K, Boes SS, Bullotta A, Dare R, Lassak M, Husain S, Kwak EJ, Paterson DL, Rinaldo CR.
    J Clin Virol; 2008 Aug; 42(4):335-42. PubMed ID: 18495527
    [Abstract] [Full Text] [Related]

  • 17. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
    Schulenburg A, Watkins-Riedel T, Greinix HT, Rabitsch W, Loidolt H, Keil F, Mitterbauer M, Kalhs P.
    Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628
    [Abstract] [Full Text] [Related]

  • 18. Comparison of quantitative competitive polymerase chain reaction-enzyme-linked immunosorbent assay with LightCycler-based polymerase chain reaction for measuring cytomegalovirus DNA in patients after hematopoietic stem cell transplantation.
    Pumannova M, Roubalova K, Vitek A, Sajdova J.
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):115-20. PubMed ID: 16406183
    [Abstract] [Full Text] [Related]

  • 19. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
    Tormo N, Solano C, Benet I, Clari MA, Nieto J, de la Cámara R, López J, López-Aldeguer N, Hernández-Boluda JC, Remigia MJ, Garcia-Noblejas A, Gimeno C, Navarro D.
    Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
    [Abstract] [Full Text] [Related]

  • 20. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 Mar; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 67.